STO · SPRINT.ST
Sprint Bioscience AB
SEK 3.50+SEK 0.06 (+1.74%)
Sprint Bioscience AB’s quoted price sits in the upper half of its reported 52-week range, 23.75% below the high.
Loading market information…
STO · HEART.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:03 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Scandinavian Real Heart AB (Publ)’s quoted price sits in the lower half of its reported 52-week range, 29.54% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Scandinavian Real Heart AB (Publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Scandinavian Real Heart AB (Publ), a Swedish enterprise established in 2007, specializes in the innovation and production of artificial heart devices. The company's core focus is the Realheart TAH, a total artificial heart engineered specifically to address severe cases of heart failure. Beyond this central project, their product portfolio also encompasses medical solutions such as the RealVAD, PulsePump, and Sternal Prosthesis. The firm operates from its base in Västerås, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:12 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 3.50+SEK 0.06 (+1.74%)
Sprint Bioscience AB’s quoted price sits in the upper half of its reported 52-week range, 23.75% below the high.
SEK 0.13+SEK 0.00 (+2.88%)
Simris Alg AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 35.9% below the high.
SEK 1.25SEK 0.00 (0.0%)
Iconovo AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 31.69% below the high.
SEK 1.23+SEK 0.09 (+7.89%)
Kontigo Care AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 49.38% below the high.
SEK 0.56SEK 0.00 (0.0%)
ScandiDos AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 57.58% below the high.
SEK 0.04+SEK 0.00 (+0.5%)
Spago Nanomedical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 80.95% below the high.
SEK 0.02+SEK 0.00 (+2.61%)
SpectraCure AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 93.5% below the high.
SEK 4.99+SEK 0.05 (+1.01%)
Luxbright AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 93.35% below the high.
